Abstract
Erenumab (Aimovig®, erenumab-aooe), a fully human monoclonal antibody (MAb) calcitonin gene-related peptide (CGRP) receptor antagonist, is the first MAb approved for the prophylaxis of migraine in adults. Erenumab is subcutaneously administered and has a convenient once-monthly/every-4-week dosing regimen. In patients with episodic or chronic migraine, erenumab is effective and generally well tolerated, significantly reducing the frequency of migraines and the use of migraine-specific medications during weeks 9–12 and months 4–6 relative to placebo. Erenumab also displays efficacy in numerous subgroup analyses, including in patients with episodic or chronic migraine with prior prophylactic treatment failure and/or patients with a history of aura. Although the efficacy and tolerability profiles of erenumab remain to be determined in specific populations (for example, in patients with major cardiovascular disease), it is a promising candidate for alleviating the widespread personal, societal and economic burdens that are presently associated with migraine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
